ALISON FEENEY: Open Payments
NPI 1578346110 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,313 in 80 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $1,939 · 2025 $2,313
Food & beverage: $2,094Education: $219
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 17 | $658 |
| Regeneron Healthcare Solutions, Inc. | 14 | $436 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $210 |
| GENZYME CORPORATION | 10 | $192 |
| Novartis Pharmaceuticals Corporation | 7 | $167 |
| SANOFI-AVENTIS U.S. LLC | 1 | $95 |
| Cycle Pharmaceuticals Inc | 3 | $78 |
| Grifols USA, LLC | 3 | $75 |
| Pharming Healthcare, Inc. | 3 | $62 |
| Genentech USA, Inc. | 3 | $61 |
Products named: DUPIXENT, AIRSUPRA, FASENRA, TEZSPIRE, HYQVIA, Sajazir, Xolair, Xembify.
Industry payments across FL — which companies pay providers there.
